Richard D. Carvajal

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, Mario Sznol, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 2.2K citations

Life Sciences, Immunology, Oncology +17

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Leora Horn, Leena Gandhi et al. · Journal of Clinical Oncology · 2015 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang et al. · Journal of Clinical Oncology · 2015 · 1.1K citations · Full text

Life Sciences, Immunology, Oncology +17

KIT as a Therapeutic Target in Metastatic Melanoma

Richard D. Carvajal · JAMA · 2011 · 878 citations

Medicine, Dermatology, Oncology +13